These updated clinical practice guidelines on the treatment of advanced (metastatic disease) nonsmall cell lung cancer, carried out by the ELCWP aim to answer the following questions: 1) What benefits can we expect from chemotherapy and which are the treatment goals? 2) Do we have to integrate a palliative approach into the cancer treatment? 3) What are the chemotherapeutic agents for which efficacy has been established? 4) Can carboplatin replace cisplatin? 5) What are the most active cisplatin-based combination chemotherapy? 6) What should be the dose of cisplatin? 7) Can non-platinum regimens replace platinum-based for first-line treatment? 8) What is the role of targeted therapies? 9) When can we or should we customize chemotherapy? 10) What is the optimal number of cycles of induction therapy to administer? Should be done consolidation or maintenance treatment? 11) Is it an indication for sequential chemotherapy? 12) What is the efficacy of salvage chemotherapy and which drugs can be given in this indication? 13) Which treatment for oligometastatic diseases? 14) What are the places of chemotherapy and radiotherapy in the treatment of patients with brain metastases? 15) Which drugs can be used specifically in cases of bone metastases? 16) Which treatment for patient unfit to receive conventional treatment because of its general status, age or comorbid conditions?